球探体育比分app下载 www.midjq.com.cn Introduction of NAFLD and NASH
       Nonalcoholic fatty liver disease (NAFLD) is defined as lipid-deposit accumulation in the hepatocytes, which is not due to excessive alcohol use. NAFLD encompasses a spectrum of diseases ranging from simple steatosis to nonalcoholic steatohepatitis (NASH), which in its most severe form can lead to liver fibrosis, cirrhosis, and hepatocellular carcinoma. The NAFLD disorder has a prevalence of 15–20% in the general population and 76–90% in the obese. It is estimated that more than 1/3 of the population worldwide will be a risk in NAFLD, which is significantly exceeding an incidence of Hepatitis B, Hepatitis C, and Alcoholic Liver Disease. NAFLD is now the most common disease of the Liver.

Innovative Candidate Compounds for NASH treatment
        
ABP-6016 is a novel drug candidate for NASH treatment . It is expected to be a new generation of innovative medicine for NASH treatment.

{ganrao} 有坂深雪做瑜伽是哪一部 丛林快讯 休闲美女麻将2代 免费成人a片创作 东北期货配资 上马麻里子喷奶在线观看 重庆时时彩人工免费计划软件 中国期货配资网 奥客竞彩比分直播 家彩网3d试机号关 足球即时指数是什么 上马麻里子作品 东京热ed2k 云南十一选五开奖结 票据理财平台哪个好 黄色片在线观看qvod